Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Executive Summary
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
You may also be interested in...
Astellas Pays $300m+ For iota In ‘Pharma-Plus’ Push
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.
SK’s Antiepileptic Speeds Japan Entry Via $500m Ono Partnership
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
Intravenous Tramadol CRL Casts Shadow On Avenue’s Cipla Deal
Avenue’s two-stage deal with an arm of Cipla faces uncertainty following a US Complete Response Letter for its intravenous tramadol. The US firm says it is "very surprised" with the potential safety concern raised and plans to seek a meeting with the agency at the earliest to resolve the issue.
Need a specific report? 1000+ reports available
Buy Reports